PURPOSE: Standardized prevalence and incidence data on carbapenem-resistant organisms (CRO) and, as a relevant subgroup, carbapenem-resistant Enterobacteriaceae (CRE) are scarce. CRO-surveillance within the German nosocomial infection surveillance system (KISS) aims to provide epidemiological surveillance data on CRO colonizations and infections. METHODS: CRO-surveillance is part of a KISS-module for the surveillance of multidrug-resistant organisms (MDRO). MDRO-KISS methods require surveillance of all patients admitted to the ward and standardized documentation of imported and ICU-acquired cases. Data on all MDRO-carriers including colonization and infection with MDRO are collected. All presented data were routine data collected from January 1st 2013 until December 1st 2013 in accordance with the German Protection against Infection Act (IfSG). RESULTS: 341 ICUs submitted data on MDRO during the first year. In total, 5,171 cases of multidrug-resistant Gram-negative bacteria (MRGN) were identified. 848 were CRO (16%). 325 CRO-cases were acquired within the ICU (38%), and 373 CRO-patients had an infection (44%). CRO-prevalence was 0.29 per 100 patients. Acquisition rate of MRGN was 1.32 per 1,000 patient days. This rate is more than doubled the acquisition rates of other MDRO under surveillance within MDRO-KISS (0.57 MRSA, 0.49 VRE). CRO-acquisition rate was 0.3 per 1,000 patient days. Incidence density of MRGN infections bacteria was 0.58 per 1,000 patient days (CRO 0.15/1,000 patient days). CONCLUSIONS: To date, CRO are common in German ICUs and the relatively large proportions of ICU-acquired CRO and infections emphasize their potential to cause outbreaks. High MRGN infection rates and high ESBL prevalence data from clinical studies suggest a lack of MRGN identification in asymptomatic carriers.
PURPOSE: Standardized prevalence and incidence data on carbapenem-resistant organisms (CRO) and, as a relevant subgroup, carbapenem-resistant Enterobacteriaceae (CRE) are scarce. CRO-surveillance within the German nosocomial infection surveillance system (KISS) aims to provide epidemiological surveillance data on CRO colonizations and infections. METHODS:CRO-surveillance is part of a KISS-module for the surveillance of multidrug-resistant organisms (MDRO). MDRO-KISS methods require surveillance of all patients admitted to the ward and standardized documentation of imported and ICU-acquired cases. Data on all MDRO-carriers including colonization and infection with MDRO are collected. All presented data were routine data collected from January 1st 2013 until December 1st 2013 in accordance with the German Protection against Infection Act (IfSG). RESULTS: 341 ICUs submitted data on MDRO during the first year. In total, 5,171 cases of multidrug-resistant Gram-negative bacteria (MRGN) were identified. 848 were CRO (16%). 325 CRO-cases were acquired within the ICU (38%), and 373 CRO-patients had an infection (44%). CRO-prevalence was 0.29 per 100 patients. Acquisition rate of MRGN was 1.32 per 1,000 patient days. This rate is more than doubled the acquisition rates of other MDRO under surveillance within MDRO-KISS (0.57 MRSA, 0.49 VRE). CRO-acquisition rate was 0.3 per 1,000 patient days. Incidence density of MRGN infections bacteria was 0.58 per 1,000 patient days (CRO 0.15/1,000 patient days). CONCLUSIONS: To date, CRO are common in German ICUs and the relatively large proportions of ICU-acquired CRO and infections emphasize their potential to cause outbreaks. High MRGN infection rates and high ESBL prevalence data from clinical studies suggest a lack of MRGN identification in asymptomatic carriers.
Authors: B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild Journal: Infection Date: 2012-06-05 Impact factor: 3.553
Authors: Lena M Biehl; Martin Schmidt-Hieber; Blasius Liss; Oliver A Cornely; Maria J G T Vehreschild Journal: Crit Rev Microbiol Date: 2014-02-04 Impact factor: 7.624
Authors: Norman Lippmann; Christoph Lübbert; Thorsten Kaiser; Udo X Kaisers; Arne C Rodloff Journal: Lancet Infect Dis Date: 2014-04 Impact factor: 25.071
Authors: P Reddy; M Malczynski; A Obias; S Reiner; N Jin; J Huang; G A Noskin; T Zembower Journal: Clin Infect Dis Date: 2007-08-20 Impact factor: 9.079
Authors: D C Richter; T Brenner; A Brinkmann; B Grabein; M Hochreiter; A Heininger; D Störzinger; J Briegel; M Pletz; M A Weigand; C Lichtenstern Journal: Anaesthesist Date: 2019-10 Impact factor: 1.041
Authors: Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen Journal: Antimicrob Agents Chemother Date: 2016-12-27 Impact factor: 5.191
Authors: Judith A Anesi; Emily A Blumberg; Jennifer H Han; Dong Heun Lee; Heather Clauss; Richard Hasz; Esther Molnar; Darcy Alimenti; Andrew R Motzer; Sharon West; Warren B Bilker; Pam Tolomeo; Ebbing Lautenbach Journal: Transpl Infect Dis Date: 2022-01-10
Authors: Falzon A Parascandalo; P Zarb; E Tartari; D Lacej; S Bitincka; O Manastirliu; D Nika; M A Borg Journal: Antimicrob Resist Infect Control Date: 2016-08-05 Impact factor: 4.887
Authors: Martin Exner; Sanjay Bhattacharya; Bärbel Christiansen; Jürgen Gebel; Peter Goroncy-Bermes; Philippe Hartemann; Peter Heeg; Carola Ilschner; Axel Kramer; Elaine Larson; Wolfgang Merkens; Martin Mielke; Peter Oltmanns; Birgit Ross; Manfred Rotter; Ricarda Maria Schmithausen; Hans-Günther Sonntag; Matthias Trautmann Journal: GMS Hyg Infect Control Date: 2017-04-10
Authors: Juri Katchanov; Lucia Asar; Eva-Maria Klupp; Anna Both; Camilla Rothe; Christina König; Holger Rohde; Stefan Kluge; Florian P Maurer Journal: PLoS One Date: 2018-04-12 Impact factor: 3.240